Lakefront Biotherapeutics (LKFT) Share-based Compensation (2016 - 2025)
Lakefront Biotherapeutics (LKFT) posted quarterly Share-based Compensation of $33.5 million for Q2 2020, up 177.31% year-over-year from $12.1 million in Q3 2019, and up 228.88% quarter-over-quarter from $10.2 million in Q1 2020.
Lakefront Biotherapeutics (LKFT) Share-based Compensation (2016 - 2025) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Share-based Compensation for 5 consecutive years, with $33.5 million the latest figure, recorded in Q2 2020.
- In Q2 2020, Share-based Compensation rose 177.31% year-over-year to $33.5 million; the TTM figure through Jun 2020 stood at $67.6 million (up 79.92% YoY), while the FY2023 annual figure was $61.0 million, down 32.42% from the prior year.
- Share-based Compensation climbed to $33.5 million in Q2 2020 per LKFT's latest filing, from $10.2 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $7.7 billion in Q2 2017 and bottomed at -$8.2 billion in Q3 2017.
- Historically, Share-based Compensation has averaged -$24.1 million across 5 years, with a median of $8.3 million in 2018.
- Annual changes were most pronounced in 2017 — Share-based Compensation jumped 289559.74% — and 2018, when it plunged 99.9%.
- Lakefront Biotherapeutics' Share-based Compensation stood at $2.6 million in 2016, then jumped by 34.63% to $3.6 million in 2017, then surged by 180.78% to $10.0 million in 2018, then rose by 12.63% to $11.3 million in 2019, then jumped by 197.62% to $33.5 million in 2020.
- Business Quant data shows LKFT's Share-based Compensation at $33.5 million in Q2 2020, $10.2 million in Q1 2020, and $11.3 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Lakefront Biotherapeutics | 1.81 Bn | -1.68 Bn | 1.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 14.33 Mn |
| Jun 30, 2025 | 14.33 Mn |
| Jun 30, 2024 | 11.00 Mn |
| Jun 30, 2024 | 11.00 Mn |
| Jun 30, 2020 | 33.50 Mn |
| Jun 30, 2020 | 33.50 Mn |
| Mar 31, 2020 | 10.19 Mn |
| Mar 31, 2020 | 10.19 Mn |
| Dec 31, 2019 | 11.26 Mn |
| Dec 31, 2019 | 11.26 Mn |
| Sep 30, 2019 | 12.66 Mn |
| Sep 30, 2019 | 12.66 Mn |
| Jun 30, 2019 | 12.08 Mn |
| Jun 30, 2019 | 12.08 Mn |
| Mar 31, 2019 | 6.82 Mn |
| Mar 31, 2019 | 6.82 Mn |
| Dec 31, 2018 | 9.99 Mn |
| Dec 31, 2018 | 9.99 Mn |
| Sep 30, 2018 | 8.68 Mn |
| Sep 30, 2018 | 8.68 Mn |